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Intra-articular Corticosteroids for Osteoarthritis of the Knee
Bruno R. da Costa, PhD; Roman Hari, MD; Peter Jüni, MD, FESC
Corticosteroids are potent anti-inflammatory agents with long-
standinguse inosteoarthritis treatment, but their effectivenessand
safety are unclear. This article summarizes the results of a recent
Cochrane review1 that evalu-
ated the association of intra-
articular corticosteroids with
benefits and harms compared with sham injection or no interven-
tion in patients with knee osteoarthritis.
Summary of Findings
Useof intra-articularcorticosteroidswasassociatedwitha largerpain
reduction thancontrol (standardizedmeandifference [SMD],−0.40
[95%CI, −0.58 to−0.22]),whichcorresponds toadifference inpain
scores of 1.0 cmona 10-cmvisual analog scale between corticoste-
roids and control. This effect size corresponds to a number needed
to treat of 8 (95% CI, 6 to 13), meaning that for every 8 patients
treatedwith corticosteroids rather than sham injection or no inter-
vention, 1 patient will respond to treatment. The Figure shows
random-effects meta-analyses by follow-up time and trial size.
Overall, corticosteroidswereassociatedwithamoderatebenefit
at 1 to2weeksaftertreatment(SMD,−0.48[95%CI,−0.70to−0.27]).
Themagnitudeofthisbeneficialassociationdecreasedwith increasing
lengthoffollow-up.Therewasnoassociationof intra-articularsteroids
withbenefitat6-monthfollow-up(SMD,−0.07[95%CI,−0.25to0.11]).
When themeta-analysiswas stratified by trial size, results from small
trialsweresimilartotheoverallanalysis.However,associationsof intra-
articularsteroidswithbenefitwerelessstronginthe3moderatetolarge
trials that included50patients ormoreper trial group.
Atest for interactionbetweentrial sizeandtreatmenteffectwas
positive (P = .01), suggestingsmall studyeffects.Findingsweresimi-
lar for physical function.Only 1 of thesemoderate to large trials that
included a total of 100patients reported adequate concealment of
allocation, adequate measures to blind patients, and an intention-
to-treat analysis.2This trial2 includedexercise therapyasaconcomi-
tant treatment inallpatients, comparedcorticosteroid injectionwith
sham injection, includedonly patientswith local signs of inflamma-
tion, and used ultrasound guidance to ensure adequate intra-
articularplacementofneedleswhen injectingasingledoseof40mg
of methylprednisolone acetate.
This trial did not find evidence that corticosteroids were asso-
ciated with clinical benefits after follow-up of 2 weeks, 3 months,
and 6months.2 The other 2moderate to large trials compared cor-
ticosteroids plus viscosupplementation vs viscosupplementation
only or corticosteroids plus joint lavage vs joint lavage only.1
Only2 trials contributedtotherandom-effectsmeta-analysesof
adverseevents,withdrawalduetoadverseevents,andseriousadverse
events.Therewasnoassociationofcorticosteroidswithadverseevents;
however, the95%CIswerewide and could not exclude thepossibil-
ityofharm.Onesmall trial foundnoevidence that intra-articular cor-
ticosteroidswere associatedwith joint space narrowing.1
Discussion
Intra-articular corticosteroidsmay be associatedwithmoderate im-
provement inpainandasmall improvement inphysical function.How-
ever, thequalityofevidence is low.Associationsof intra-articular ste-
roids with benefit decreased over time. Therewas no association of
intra-articular steroidswith benefit at 6-month follow-up.
Limitations
First, thequality of theevidencewasgenerally low, therewas consid-
erableheterogeneityamongtrials,andtherewasevidenceofsmallstudy
effects. Heterogeneity estimates and associations with benefit de-
creasedwhenanalyseswere restricted to trialswithappropriate con-
cealmentofallocation,nonindustryfunding,moderateto largesample
Editorial page 2607
CLINICAL QUESTION Are intra-articular corticosteroids associated with improvement in pain and
physicalfunctioncomparedwithshaminjectionornointerventioninpatientswithkneeosteoarthritis?
BOTTOM LINE Intra-articular corticosteroids may be associated withmoderate improvement
in pain and a small improvement in physical function up to 6 weeks after injection. However,
the quality of the evidence is low.
Evidence Profile
No. of studies: 27
No. of randomized clinical trials: 27
Study years: Conducted, 1954-2014; published, 1958-2015
No. of participants: 1767
Male: 39% Female: 61%
Race/ethnicity:Not reported
Age, mean (range): 63 years (42-71 years)
Settings:Outpatient clinics in rheumatology, surgery, physical
medicine and rehabilitation, anesthesia and pain management,
and general practice
Countries: Australia, Belgium, Brazil, Canada, Curaçao, Denmark,
France, Italy, the Netherlands, Russia, Scotland, Spain, Sweden,
Turkey, United Kingdom, United States
Comparison: Intra-articular corticosteroids compared with sham
injection or no intervention in patients with knee osteoarthritis
Primary outcomes: Change in pain and physical function
Secondary outcomes:Quality of life, any adverse events,withdrawal
due to adverse events, serious adverse events, joint spacenarrowing
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sizes,oruseofviscosupplementationor joint lavageascointerventions
inbothgroups.1Findingsweresimilarforphysicalfunction.Second,point
estimates were imprecise and we cannot exclude an association be-
tweencorticosteroids and clinically relevant benefits or harm.
Third, none of the included trials focused on patients with in-
termittent osteoarthritic flares, and only 2 trials had eligibility cri-
teria compatible with the predominant inclusion of patients with
acuteor subacuteexacerbationsof symptoms.2,3Therefore, it is not
possible to draw conclusions about the association of corticoste-
roids with benefit in patients with acute or subacute worsening of
symptoms after minor trauma or physical activity with signs of lo-
cal inflammation, effusion, or both.
Comparison of FindingsWith Current Guidelines
The findingsareconsistentwith the2013guidelinesof theAmerican
Academy ofOrthopaedic Surgeons, which did not provide any rec-
ommendations fororagainst theuseof intra-articularcorticosteroids
because theevidencewas inconclusive.4The2012guidelinesof the
AmericanCollegeofRheumatologyconditionally recommend intra-
articular steroids forkneeosteoarthritis.5The2014National Institute
forHealthandCareExcellenceguidelines recommendthatclinicians
consider theuseof corticosteroidsasanadjunct tocore treatments.
Our findingsare formallyconsistentwith theserecommendations.5,6
The 2014Osteoarthritis Research Society International guidelines7
state that intra-articular corticosteroids are appropriate for knee
osteoarthritis, which somewhat differs fromour conclusion.
Areas in Need of Future Study
Adequately powered trials are needed to confirm or refute clini-
cally relevant short- to midterm benefits of intra-articular cortico-
steroids in patients with stable disease, and in patients with inter-
mittent exacerbations of their osteoarthritis symptoms. The trials
shouldhaveashaminjectioncontrolgroup,anduseultrasoundguid-
ance to ensure accurate intra-articular needle placement.2
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Figure. Associations of Intra-articular CorticosteroidsWith Knee Pain in Randomized Clinical Trials of Knee Osteoarthritis
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Severity of Knee Pain
No. Needed to
Treat (95% CI)a
16 10421-2 wk –0.48 (–0.70 to –0.27) 5 (4 to 10)
22 15294-6 wk –0.41 (–0.61 to –0.21) 6 (4 to 13)
18 12333 mo –0.22 (–0.44 to 0) 12 (6 to ∞)
7 5266 mo –0.07 (–0.25 to 0.11) 39 (11 to ∞)
Moderate to large trials c
2 2041-2 wk –0.33 (–0.89 to 0.24) 8 (3 to ∞)
2 3084-6 wk –0.18 (–0.58 to 0.22) 15 (4 to ∞)
3 3983 mo 0.07 (–0.13 to 0.27) ∞ (22 to ∞)
2 1936 mo –0.06 (–0.34 to 0.23) 51 (8 to ∞)
Small trials
14 8381-2 wk –0.51 (–0.76 to –0.27) 5 (3 to 10)
20 12214-6 wk –0.44 (–0.66 to –0.22) 6 (4 to 12)
15 8353 mo –0.29 (–0.56 to –0.03) 9 (5 to 110)
5 3336 mo –0.08 (–0.33 to 0.17) 35 (8 to ∞)
a To derive from standardizedmean differences, a probability of treatment
response in the control group of 31%was assumed, with response defined as
50% or greater decrease in pain from baseline.1 The symbol reported for the
point estimate or 95% CI of the number needed to treat (NNT) indicates that
the corresponding estimate was in favor of control (ie, the risk difference used
to generate the NNT, which is the inverse of the risk difference, was negative,
indicating that patients in the control group weremore likely to respond to
treatment than those receiving corticosteroids).
b Trials assessed pain using self-reported instruments such as a 10-cm visual
analog scale.
c Included 50 or more patients per trial group.
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